Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]-1- benzylpiperidine for the dopamine transporter: Effect of different aromatic substitutions on their affinity and selectivity

Journal of Medicinal Chemistry

Volumn 40, Issue 1, 1997, Pages 35-43

  Dutta, Aloke K ^a   Coffey, Lori L ^b   Reith, Maarten E A ^b  

^a ORGANIX INC   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 [2 (DIPHENYLMETHOXY)ETHYL] 1 [(4 FLUOROPHENYL)METHYL]PIPERIDINE; 4 [2 (DIPHENYLMETHOXY)ETHYL] 1 [(4 NITROPHENYL)METHYL]PIPERIDINE; 4 [2 (DIPHENYLMETHOXY)ETHYL] 1 BENZYLPIPERIDINE DERIVATIVE; 4 [2 [(2 THIENYL)PHENYLMETHOXY]ETHYL] 1 [(4' FLUOROPHENYL)METHYL]PIPERIDINE; DOPAMINE; DOPAMINE TRANSPORTER; SEROTONIN; UNCLASSIFIED DRUG; VANOXERINE;

ARTICLE; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG BINDING; DRUG COMPETITION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARRIER PROTEINS; CITALOPRAM; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PIPERAZINES; RATS;

EID: 0031021652     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960638e     Document Type: Article

References (42)

1. Musto, D. F. Opium, Cocaine and Marijuana in American History. Sci. Am. 1991, 256, 40-47.
2. Clouet, D., Ashgar, K., Brown, R., Eds. Mechanism of Cocaine Abuse and Toxicity. NIDA Res. Monogr. 1988, 88.
3. Johanson, C. E.; Fischman, M. W. The Pharmacology of Cocaine Related to its Abuse. Pharmacol. Rev. 1989, 41 (1), 3-52.
4. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14, 299-302.
5. Robinson, T.; Barridge, K. C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res. Rev. 1993, 18, 249-291.
6. Ritz, M. C.; Lamb, R. J.; Goldberg, R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-adminstration of cocaine. Science 1987, 237, 1219-1223.
7. Volkow, N. D.; Ding, Y.-S.; Fowler, J. S.; Wang, G.-J.; Logan, J.; Gatley, J. S.; Dewy, S.; Ashby, C.; Lieberman, J.; Hitzemann, R.; Wolf, A. P. Is methylphenidate like cocaine? Arch. Gen. Psychiatry 1995, 52, 456-463.
8. 3H]cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 1989, 251, 131-141.
9. Reith, M. E. A.; Meisler, B. E.; Sershen, H.; Lajtha, A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem. Pharmacol. 1986, 35, 1123-1129.
10. Kuhar, M. J. Neurotransmitter Uptake: A tool in identifying neurotransmitter-specific pathways. Life Sci. 1973, 13, 1623-1634.
11. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379, 606-612.
12. Kotian, P.; Mascarella, S. W.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J.; Carroll, F. I. Synthesis, Ligand Binding, and Quantitative Structure-Activity Relationship Study of 3β-(4′-Substituted phenyl)-2β-heterocyclic Tropanes: Evidence for an Electrostatic Interaction at the 2b-Position. J. Med. Chem. 1996, 39, 2753-2763.
13. Carroll, F. I.; Mascarella, S. W.; Kuzemko, M. A.; Gao, Y.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Synthesis, Ligand Binding, and QSAR (CoMFA and Classical) Study of 3β-(3′-Substituted phenyl)-, 3β-(4′-Substituted phenyl)-, and 3β-(3′, 4′-Disubstituted phenyl)tropane-2β-carboxylic Acid Methyl Esters. J. Med. Chem. 1994, 37, 2865-2873.
14. Meltzer, P. C.; Liang, A. Y.; Brownell, A.-L.; Elmaleh, D. R.; Madras, B. K. Substituted 3-phenyltropane analogs of cocaine: Synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J. Med. Chem. 1993, 36, 855-862.
15. Carroll, F. I.; Kotian, P.; Dehghani, A.; Gray, J. L.; Kuzemko, M. A.; Parham, K. A.; Abraham, P.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine and 3β-(4′-substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J. Med. Chem. 1995, 38, 379-388.
16. 3H]GBR 12935: A specific high affinity ligand for labelling the dopamine transport complex. Eur. J. Pharmacol. 1985, 107, 289-290.
17. 125I]RTI-55: A potent ligand for dopamine transporters. Eur. J. Pharmacol. 1991, 194, 133-134.
18. 3H]Cocaine Binding in Central Nervous System of Mouse. Life Sci. 1980, 27, 1055-1062.
19. Van der Zee, P.; Koger, H. S.; Gootjes, J.; Hespe, W. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
20. 3H]GBR 12935 binding in vitro to rat striatal membranes: labelling of the dopamine uptake complex. J. Neurochem. 1987, 48, 1887-1896.
21. Anderson, P. H. The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur. J. Pharmacol. 1989, 166, 493-504.
22. Rothman, R. B.; Mele, A.; Reid, A. A.; Akunne, H. C.; Greig, N.; Thurkauf, A.; de Costa, B. R.; Rice, K. C.; Pert, A. GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav. 1991, 40, 387-397.
23. Bauman, M. H.; Char, G. U.; De Costa, B. R.; Rice, K. C.; Rothman, R. B. GBR 12909 Attenuates Cocaine-Induced Activation of Mesolimbic Dopamine Neurons in the Rat. J. Pharmacol. Exp. Ther. 1994, 271, 1216-1222.
24. Wojnicki, F. H. E.; Glowa, J. R. Effects of Drug History on the Acquisition of Responding Maintained by GBR 12909 in Rhesus Monkeys. Psychopharmacology 1996. 123, 34-41.
25. Howell, L. L.; Byrd, L. D. Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. J. Pharmacol. Exp. Ther. 1991, 258, 178-185.
26. Glowa J. R.; Wojnicki, F. H.; De Costa, B. R.; Matecka, D.; Rice, K. C.; Rothman, R. B. The effects of GBR 12909 on responding of rhesus monkeys maintained under schedules of cocaine- and food-delivery. NIDA Res. Monogr. 1994, 141, 12.
27. Sogaard, U.; Michalow, J.; Butler, B.; Lund Laursen, A.; Ingersen, S. H.; Skrumsager, B. K.; Rafaelsen, O. J. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int. Clin. Psychopharmacol. 1990, 5, 237-251.
28. Dutta, A. K.; Meltzer, P. C.; Madras, B. K. Positional importance of the nitrogen atom in novel piperidine analogs of GBR 12909: Affinity and selectivity for the dopamine transporter. Med. Chem. Res. 1993, 3, 209-222.
29. Dutta A. K.; Xu, C.; Reith, M. E. A. Structure-Activity Relationship Studies of Novel 4-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine Analogs: Synthesis and Biological Evaluation at the Dopamine and Serotonin Transporter Sites. J. Med. Chem. 1996, 39, 749-756.
30. Madras, B. K.; Reith, M. E. A.; Meltzer, P. C.; Dutta, A. K. O-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen. Eur. J. Pharmacol. 1994, 267, 167-173.
31. Rothman R.; Lewis, B.; Dersch, C.; Xu, H.; Radesca, L.; de Costa, B. R.; Rice, K. R.; Kilburn, R. B.; Akunne, H. C.; Pert, A. Identification of a GBR 12935 homolog, LR 111, which is over 4,000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse 1993, 14, 34-39.
32. Matecka D.; Rice, K. C.; Rothman, R. B.; De Costa, B.; Glowa, J. R.; Wojnicki, F. H.; Pert, A.; George, C.; Carroll, F. I.; Silverthorn, M. L.; Dersch, C. M.; Becketts, K. M.; Partilla, J. S. Synthesis and Absolute Configuration of Chiral Piperazines Related to GBR 12909 as Dopamine Reuptake Inhibitors. Med. Chem. Res. 1994, 5, 43-53.
33. Meltzer, P. C.; Liang, A. Y.; Madras, B. K. 2-Carbomethoxy-3-(diarylmethoxy)-1αH, 5αH-tropane Analogs: Synthesis and Inhibition of Binding at the Dopamine Transporter and Comparison with Piperazines of the GBR Series. J. Med. Chem. 1996, 39, 371-379.
34. Clarke, R. L.; Daum, S. J.; Gambino, A. J.; Aceto, M. D.; Pearl, J.; Levitt, M.; Cumiskey, W. R.; Bogado, E. F. Compounds affecting the central nervous system. 4. 3β-phenyltropane-2-carboxylic esters and analogues. J. Med. Chem. 1973, 16, 1260-1267.
35. Carroll F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine receptor: Biochemical characterization and structure-activity relationship of cocaine analogues at the dopamine transporter. J. Med. Chem. 1992, 35, 969-981.
36. Kozikowski, A. P.; Eddine Saiah, M. K.; Johnson, K. M.; Bergmann, J. S. Chemistry and biology of the 2β-alkyl-3β-phenyl analogues of cocaine: subnanomolar affinity ligands that suggest a new pharmacophore model at the C-2 position. J. Med. Chem. 1995, 38, 3086-3093.
37. Srivastava, S.; Crippen, G. M. Analysis of cocaine receptor site ligand binding by three-dimensional Voronoi site modeling approach. J. Med. Chem. 1993, 36, 3572-3579.
38. Deutsch, H. M.; Schweri, M. M.; Culbertson, C. T.; Zalkow, L. H. Synthesis and pharmacology of irreversible affinity labels as potential cocaine antagonists: aryl 1,4-dialkylpiperazines related to GBR-12783. Eur. J. Pharmacol. 1992, 220, 173-180.
39. Curtin, D. Y.; Leskowitz, S. Cleavage and rearrangement of ethers with base. II. reaction of the benzhydryl and trityl ethers of benzoin with potassium hydroxide. J. Am. Chem. Soc. 1951, 73, 2633-2636.
40. Borch, R. F.; Bernstein, M. D.; Durst, H. D. The cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1972, 94, 2897-2904.
41. Brown, H. C.; Rao Subba, B. C. A new powerful reducing agent-sodium borohydride in the presence of aluminum chloride and other polyvalent metal halides. J. Am. Chem. Soc. 1956, 78, 2582-2588.
42. Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug Res. 1991, 37, 287-371.